Clinical trials / NCT07037511
Recruiting

Effects of Salbutamol in Athletes and Implications for Screening and Sports

β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to…

ClinicalTrials.gov IDNCT07037511
PhaseNA
Enrollment64
SponsorUniversity of British Columbia
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Asthma, Healthy, Effect of Drug

About this study

β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Aerobic capacity (V̇O2max) greater than 120% predicted * Body mass index (BMI) \> 18 and \< 30 kg/m2 * Ability to read and understand English * Currently training and/or competing in endurance sports (i.e. running or cycling) Exclusion Criteria: * Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day / 200 (number of puffs in a pack of cigarettes). * Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year. * Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime. * History or current symptoms of cardiopulmonary disease (excluding controlled asthma) * Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle) * Neuromuscular or musculoskeletal condition

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.